Table 3.
PSA Change From Baselinea | Level 1 (n = 33) N (%) | Level 2 (n = 2) N (%) | Level 3 (n = 4) N (%) | Total (n = 39) N (%) |
Maximum decline | ||||
≥30% | 25 (81) | 2 (100) | 3(75) | 30 (77) |
≥50% | 24 (77) | 1 (50) | 3(75) | 38 (72) |
Decline at 12 wk | ||||
≥30% | 22 (67) | 2 (100) | 2(50) | 26 (67) |
≥50% | 21 (64) | 1 (25) | 1 (25) | 23 (59) |
RECIST | Level 1 (n = 22) N (%) | Level 2 (n = 2) N (%) | Level 3 (n = 1) N (%) | Total (n = 25) N (%) |
Stable disease | 4(18) | 1 (50) | 5(20) | |
Partial response | 18 (82) | 1 (100) | 19 (76) | |
Complete response | 1 (5) | 1 (4) |
Abbreviations: PSA = prostate-specific antigen; RECIST = Response Evaluation Criteria In Solid Tumors.
Baseline PSA ≥ 2 ng/mL.